RhumbLine Advisers
LSTA icon

RhumbLine Advisers’s Lisata Therapeutics LSTA Stock Holding History

RhumbLine Advisers’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-192
Closed -$73K – 3061
2015
Q1 		$73K Buy
192
+21
+12% +$11.4K ﹤0.01% 2984
2014
Q4 		$97K Buy
171
+11
+7% +$7.49K ﹤0.01% 2964
2014
Q3 		$132K Buy
160
+9
+6% +$7.88K ﹤0.01% 2886
2014
Q2 		$147K Buy
+151
New +$147K ﹤0.01% 2927

Other funds holding LSTA

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RhumbLine Advisers's LSTA Position: Q2 2015 in Review

RhumbLine Advisers sold out of Lisata Therapeutics (LSTA) in Q2 2015, closing a stake of 192 shares — an estimated $73K sold.

RhumbLine Advisers first reported a position in LSTA in Q2 2014 and held it in 4 quarters. The position peaked at $147K in Q2 2014. 51 funds tracked by Wall St. Rank hold LSTA as of Q2 2015.

  • RhumbLine Advisers reported no remaining Lisata Therapeutics position as of Q2 2015 after selling out during the quarter.
  • RhumbLine Advisers sold 192 Lisata Therapeutics shares in Q2 2015, an estimated $73K.
  • RhumbLine Advisers first reported a position in Lisata Therapeutics in Q2 2014 and held it in 4 quarters.
  • RhumbLine Advisers's Lisata Therapeutics position peaked at $147K in Q2 2014.
  • 51 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q2 2015.

Based on RhumbLine Advisers's 13F filing for Q2 2015, filed 4 Aug 2015.